Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study

Show other versions (2)

Bibliographic Details
Main Authors:	Rosario, D, Lane, J, Metcalfe, C, Donovan, J, Doble, A, Goodwin, L, Davis, M, Catto, J, Avery, K, Neal, D, Hamdy, F
Format:	Journal article
Published:	2012

Similar Items

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
by: Rosario, D, et al.
Published: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
by: Rosario, D, et al.
Published: (2012)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
by: Rosario, D, et al.
Published: (2008)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.
by: Avery, K, et al.
Published: (2012)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy
by: Avery, K, et al.
Published: (2012)

The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)
by: Lane, J, et al.
Published: (2004)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
by: Collin, S, et al.
Published: (2009)

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
by: Hamdy, F, et al.
Published: (2006)

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
by: J. Donovan, et al.
Published: (2003-01-01)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.
by: Catto, J, et al.
Published: (2011)

Suitability of PSA-detected localised prostate cancers for focal therapy: Experience from the ProtecT study
by: Catto, J, et al.
Published: (2011)

Association of obesity with prostate cancer: A case-control study within the population-based PSA testing phase of the ProtecT study
by: Dimitropoulou, P, et al.
Published: (2011)

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study.
by: Dimitropoulou, P, et al.
Published: (2011)

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.
by: Burton, A, et al.
Published: (2013)

Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?
by: Avery, K, et al.
Published: (2008)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
by: Lane, J, et al.
Published: (2010)

Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
by: Macefield, R, et al.
Published: (2009)

Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial
by: Johnston, T, et al.
Published: (2016)

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial
by: Wade, J, et al.
Published: (2015)

Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study.
by: Zuccolo, L, et al.
Published: (2013)

Experiences and decision processes during PSA testing and prostate biopsy: A qualitative study
by: Avery, K, et al.
Published: (2007)

Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK.
by: Down, L, et al.
Published: (2011)

Seasonal variation in prostate-specific antigen levels: A large cross-sectional study of men in the UK
by: Down, L, et al.
Published: (2011)

Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protecT randomised controlled trial according to treatment received
by: Neal, D, et al.
Published: (2019)

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
by: Lane, A, et al.
Published: (2016)

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial.
by: Er, V, et al.
Published: (2017)

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: The ProtecT three-arm RCT
by: Hamdy, FC, et al.
Published: (2020)

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
by: S. Sanghera, et al.
Published: (2020-10-01)

Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study.
by: Mills, N, et al.
Published: (2003)

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).
by: Donovan, J, et al.
Published: (2003)

Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result.
by: Macefield, R, et al.
Published: (2010)

Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer.
by: Collin, S, et al.
Published: (2010)

Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.
by: Tilling, K, et al.
Published: (2010)

The Prostate Testing for Cancer and Treatment (ProtecT) study: what have we learnt?
by: Hamdy, F
Published: (2017)

Prostate cancer detection in men aged 45-49 years in the UK protect (prostate testing for cancer and treatment) trial
by: Hamdy, F, et al.
Published: (2006)

A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study).
by: Mills, N, et al.
Published: (2006)

ASSOCIATIONS OF SEXUAL DYSFUNCTION WITH LOCALIZED AND ADVANCED PROSTATE CANCER: A CASE-CONTROL STUDY NESTED WITHIN THE UK POPULATION-BASED PROTECT (PROSTATE TESTING FOR CANCER AND TREATMENT) STUDY
by: Collin, S, et al.
Published: (2009)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
by: Vickers, A, et al.
Published: (2010)

Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
by: Avery, K, et al.
Published: (2008)

Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
by: Brindle, L, et al.
Published: (2006)